Vivatides Raises $54 Million Series A to Advance Extrahepatic RNA Therapeutics Platform

New updates have been reported about Vivatides Therapeutics.

Vivatides Therapeutics has closed an oversubscribed $54 million Series A round to accelerate its extrahepatic RNA therapeutics platform, marking its second financing within a year of its 2025 founding and signaling strong investor conviction in its delivery technology and execution. The round was co-led by Qiming Venture Partners and a major industry fund, with additional participation from Highlight Capital, TF Capital, and returning backer Apricot Capital, and the capital will be directed toward advancing the company’s delivery science, moving multiple candidates into the clinic, and expanding its global R&D and management footprint.

Positioned at the emerging frontier of RNA medicines beyond the liver, Vivatides is developing proprietary delivery technologies for siRNA and antisense oligonucleotides that target extrahepatic tissues implicated in high-prevalence chronic diseases such as cardiovascular and oncologic indications. The company reports progress in ligand conjugation, tissue-specific targeting, delivery efficiency, and safety backed by encouraging in vivo data, and plans to accelerate preclinical optimization and IND-enabling studies to convert its discovery pipeline into clinical-stage assets. Founder Keming Zhou highlighted extrahepatic delivery as the key to scaling RNA therapeutics from niche rare diseases to large chronic markets, while lead investors from Qiming and Apricot cited Vivatides’ technical depth and rapid execution as reasons for their support and expectations for further breakthroughs. Executives should view this financing as a capacity-building step that strengthens Vivatides’ position in a rapidly expanding therapeutic modality and enhances its ability to secure future partnerships, attract talent, and compete for leadership in extrahepatic RNA delivery.